{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T09:16:16Z","timestamp":1771060576410,"version":"3.50.1"},"reference-count":107,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:p>Anaplastic large-cell lymphoma is a rare disease and account for approximately 10% to 15% of pediatric non-Hodgkin lymphomas. They are characterized by extended stages, a high frequency of B signs and extra nodal involvement. Multiagent chemotherapy cures \u223d60% to 75% of patients and relapse occurs in 35% of cases. For relapsed patients, various treatments ranging from vinblastine monotherapy to therapeutic intensification with hematopoietic stem cell transplantation have been evaluated, but there is currently no consensus on the optimal therapeutic strategy. New therapeutic perspectives are being evaluated for relapses and refractory forms as well as high-risk forms including monoclonal antibodies (Anti CD30), ALK inhibitors, and CART cells.<\/jats:p>","DOI":"10.1097\/mph.0000000000002875","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T09:23:03Z","timestamp":1719220983000},"page":"217-224","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Anaplastic Large-cell Lymphoma in Children: State of the Art in 2023"],"prefix":"10.1097","volume":"46","author":[{"given":"Nisrine","family":"Khoubila","sequence":"first","affiliation":[{"name":"Department of Hematology and Pediatric Oncology, Hospital 20 August 1953, CHU Ibn Rochd, Faculty of Medicine and Pharmacy, Hassan II University, Casablanca"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia","family":"Sraidi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Pediatric Oncology, Hospital 20 August 1953, CHU Ibn Rochd, Faculty of Medicine and Pharmacy, Hassan II University, Casablanca"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdellah","family":"Madani","sequence":"additional","affiliation":[{"name":"Department of Hematology and Pediatric Oncology, Hospital 20 August 1953, CHU Ibn Rochd, Faculty of Medicine and Pharmacy, Hassan II University, Casablanca"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Illias","family":"Tazi","sequence":"additional","affiliation":[{"name":"Department of Clinical Hematology, CHU Mohamed VI, Cadi Ayyad University, Marrakech, Morocco"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,6,24]]},"reference":[{"key":"R1-20250804","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/blood.V66.4.848.848","article-title":"The expression of the Hodgkin\u2019s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells","volume":"66","author":"Stein","year":"1985","journal-title":"Blood"},{"key":"R2-20250804","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/cncr.10396","article-title":"A population-based study of pediatric anaplastic large cell lymphoma","volume":"94","author":"Alessandri","year":"2002","journal-title":"Cancer"},{"key":"R3-20250804","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1136\/jcp.50.2.128","article-title":"Childhood non-Hodgkin lymphomas in the united kingdom: findings from the UK children\u2019s cancer study group","volume":"50","author":"Wright","year":"1997","journal-title":"J Clin Pathol"},{"key":"R4-20250804","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"R5-20250804","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: a proposal from the international lymphoma study group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"key":"R7-20250804","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1182\/blood.V96.12.3681","article-title":"CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features","volume":"96","author":"Stein","year":"2000","journal-title":"Blood"},{"key":"R8-20250804","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1200\/JCO.1994.12.5.899","article-title":"Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster groupe studies","volume":"12","author":"Reiter","year":"1994","journal-title":"J Clin Oncol"},{"key":"R9-20250804","first-page":"3591","article-title":"CD30(+) anaplastic large-cell lymphoma in children :analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology","volume":"92","author":"Brugi\u00e8res","year":"1998","journal-title":"Blood"},{"key":"R11-20250804","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1200\/JCO.2014.59.7203","article-title":"Revised international pediatric Non-Hodgkin lymphoma staging system","volume":"33","author":"Rosolen","year":"2015","journal-title":"J Clin Oncol"},{"key":"R12-20250804","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/pbc.24125","article-title":"Results of AIEOP LNH-97 protocol for the treatment of anaplastic large cell lymphoma of childhood","volume":"59","author":"Pillon","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"R13-20250804","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1182\/blood.V97.12.3699","article-title":"Short-pulse B non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90","volume":"97","author":"Seidemann","year":"2001","journal-title":"Blood"},{"key":"R14-20250804","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1002\/cncr.21438","article-title":"Anaplastic large cell lymphoma treated with a leukemia-like therapy : report of the Italian Association of Pediatric Hematology and Oncology (AIEOP) LNH-92 protocol","volume":"104","author":"Rosolen","year":"2005","journal-title":"Cancer"},{"key":"R15-20250804","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/MPH.0b013e31819146f8","article-title":"Long-term disease control of refractory anaplastic large cell lymphoma with vinblastine","volume":"31","author":"Garner","year":"2009","journal-title":"J Pediatr Hematol Oncol"},{"key":"R16-20250804","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1200\/JCO.2011.34.8417","article-title":"Relapsed or refractory anaplastic large-cell lymphoma in children and adolescents after Berlin-Frankfurt-Muenster (BFM)-type first-line therapy: a BFM-group study","volume":"29","author":"Woessmann","year":"2011","journal-title":"J Clin Oncol"},{"key":"R17-20250804","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1046\/j.1365-2141.2003.04249.x","article-title":"Anaplastic large cell lymphoma in Japanese children: retrospective analysis of 34 patients diagnosed at the National Research Institue for Child Health and Development","volume":"121","author":"Mori","year":"2003","journal-title":"Br J Haematol"},{"key":"R18-20250804","first-page":"188","article-title":"Large-cell anaplastic (Ki-1-positive) lymphoma complicated by disseminated intravascular coagulation","volume":"115","author":"Arber","year":"1991","journal-title":"Arch Pathol Lab Med"},{"key":"R19-20250804","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1182\/blood-2007-07-100958","article-title":"Prognostic factors in childhood anaplastic large cell lymphoma: results of a large European intergroup study","volume":"111","author":"Le Deley","year":"2008","journal-title":"Blood"},{"key":"R20-20250804","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3109\/08880018.2013.805347","article-title":"Anaplastic large cell lymphoma in children and adolescents","volume":"30","author":"Lowe","year":"2013","journal-title":"Pediatr Hematol Oncol"},{"key":"R21-20250804","doi-asserted-by":"crossref","first-page":"E118","DOI":"10.1002\/pbc.24591","article-title":"Central nervous system involvement in anaplastic large cell lymphoma in childhood: results from a multicentre European and Japanese study","volume":"60","author":"Williams","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"R22-20250804","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/ajh.24065","article-title":"ALK-positive anaplastic large cell lymphoma presenting with hemophagocytic lymphohistiocytosis","volume":"90","author":"Shah","year":"2015","journal-title":"Am J Hematol"},{"key":"R23-20250804","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/bjh.12728","article-title":"Clinical analysis and prognostic significance of haemophagocytic lymphohistiocytosis-associated anaplastic large cell lymphoma in children","volume":"165","author":"Pasqualini","year":"2014","journal-title":"Br J Haematol"},{"key":"R24-20250804","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/MPH.0b013e3181979c5e","article-title":"Primary testicular presentation of ALK-1-negative anaplastic large cell lymphoma in a pediatric patient","volume":"31","author":"Lagmay","year":"2009","journal-title":"J Pediatr Hematol Oncol"},{"key":"R25-20250804","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1046\/j.1365-2141.2002.03482.x","article-title":"Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on The United Kingdom Children\u2019s Cancer Study Group chemotherapy regimens","volume":"117","author":"Williams","year":"2002","journal-title":"Br J Haematol"},{"key":"R26-20250804","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/RLU.0000000000002929","article-title":"Anaplastic large cell lymphoma involving 7 different organs in a pediatric patient demonstrated by FDG PET\/CT","volume":"45","author":"Zhang","year":"2020","journal-title":"Clin Nucl Med"},{"key":"R27-20250804","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00259-004-1604-z","article-title":"18F-FDG PET in children with lymphomas","volume":"32","author":"Depas","year":"2005","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R28-20250804","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/RLU.0000000000002927","article-title":"Pronostic value of 18F-FDG PET\/CT-metabolic parameters at baseline and interim assessment in pediatric anaplastic large cell lymphoma","volume":"45","author":"Mathew","year":"2020","journal-title":"Clin Nucl Med"},{"key":"R29-20250804","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40644-019-0278-5","article-title":"18F-FDG PET\/CT imaging findings in anaplastic large cell lymphom, a rare subtype of lymphoma","volume":"20","author":"Jiang","year":"2020","journal-title":"Cancer Imaging"},{"key":"R30-20250804","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/00000478-199309000-00001","article-title":"A small-cell-predominant variant of primary Ki-1 (CD30)+ T-cell lymphoma","volume":"17","author":"Kinney","year":"1993","journal-title":"Am J Surg Pathol"},{"key":"R31-20250804","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1182\/blood.V91.6.2076","article-title":"ALK-positive lymphoma: a single disease with a broad spectrum of morphology","volume":"91","author":"Benharroch","year":"1998","journal-title":"Blood"},{"key":"R32-20250804","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.1365-2141.2009.07754.x","article-title":"Distribution of NPM1-ALK and X-ALK fusion transcripts in paediatric anaplastic large cell lymphoma: a molecular-histological correlation","volume":"146","author":"Damm-Welk","year":"2009","journal-title":"Br J Haematol"},{"key":"R33-20250804","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3324\/haematol.2009.014050","article-title":"C\/EBP\u03b2 expression in ALK-positive anaplastic large cell lymphomas is required for cell proliferation and is induced by the STAT3 signaling pathway","volume":"95","author":"Anastasov","year":"2010","journal-title":"Haematologica"},{"key":"R34-20250804","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1200\/JCO.2011.36.5411","article-title":"Prognostic impact of morphologic and phenotypic features of childhood ALK-positive anaplastic large-cell lymphoma: results of the ALCL99 study","volume":"29","author":"Lamant","year":"2011","journal-title":"J Clin Oncol"},{"key":"R35-20250804","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/leu.2012.205","article-title":"Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK positive ALCL patients with different prognosis","volume":"27","author":"Mussolin","year":"2013","journal-title":"Leukemia"},{"issue":"uppl 1","key":"R36-20250804","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1080\/10245330512331390087","article-title":"Hemophagocytic lymphhistiocytosis","volume":"10","author":"Janka","year":"2005","journal-title":"Hematology"},{"key":"R37-20250804","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1182\/blood.V75.2.434.434","article-title":"Peripheral T-cell lymphoma associated with hemophagocytic syndrome","volume":"75","author":"Falini","year":"1990","journal-title":"Blood"},{"key":"R38-20250804","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1046\/j.1365-2133.2001.04025.x","article-title":"Lymphomatoid papulosis in children: a study of 10 children registered by the Dutch Cutaneous Lymphoma Working Group","volume":"144","author":"Van Neer","year":"2001","journal-title":"Br J Dermatol"},{"key":"R39-20250804","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"R40-20250804","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1073\/pnas.93.9.4181","article-title":"Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5)","volume":"93","author":"Fujimoto","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"R41-20250804","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1128\/MCB.17.4.2312","article-title":"Role of the nucleophosmin (NPM) portion of the non-Hodgkin\u2019s lympho-ma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis","volume":"17","author":"Bischof","year":"1997","journal-title":"Mol Cell Biol"},{"key":"R42-20250804","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/sj.onc.1205152","article-title":"Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death","volume":"21","author":"Zamo","year":"2002","journal-title":"Oncogene"},{"key":"R43-20250804","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/leu.2017.103","article-title":"PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma","volume":"31","author":"Atsaves","year":"2017","journal-title":"Leukemia"},{"key":"R44-20250804","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.humpath.2017.10.029","article-title":"Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes","volume":"71","author":"Panjwani","year":"2018","journal-title":"Hum Pathol"},{"key":"R45-20250804","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/PAS.0000000000000500","article-title":"Morphologic features of ALK-negative anaplastic large cell lymphomas with DUSP22 rearrangements","volume":"40","author":"King","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R46-20250804","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ccell.2015.03.006","article-title":"Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma","volume":"27","author":"Crescenzo","year":"2015","journal-title":"Cancer Cell"},{"key":"R47-20250804","first-page":"332","article-title":"Classification, staging and end results of treatment of childhood non-Hodgkin\u2019s lymphomas: dissimilarities from lymphomas in adults","volume":"7","author":"Murphy","year":"1980","journal-title":"Semin Oncol"},{"key":"R48-20250804","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","article-title":"Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin\u2019s disease: Cotswolds meeting","volume":"7","author":"Lister","year":"1989","journal-title":"J Clin Oncol"},{"key":"R49-20250804","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/sj.leu.2403888","article-title":"Prevalence and clinical implications of bone marrow involvement in pediatric anaplastic large cell lymphoma","volume":"19","author":"Mussolin","year":"2005","journal-title":"Leukemia"},{"key":"R50-20250804","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1182\/blood-2007-02-066852","article-title":"prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK-positive anaplastic large-cell lymphoma","volume":"110","author":"Damm-Welk","year":"2007","journal-title":"Blood"},{"key":"R51-20250804","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1182\/blood-2009-11-251892","article-title":"Correlation of the anutoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk","volume":"115","author":"Ait-Tahar","year":"2010","journal-title":"Blood"},{"key":"R52-20250804","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/blood-2013-09-526202","article-title":"Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK-positive anaplastic large-cell lymphoma","volume":"123","author":"Damm-Welk","year":"2014","journal-title":"Blood"},{"key":"R53-20250804","doi-asserted-by":"crossref","first-page":"5056","DOI":"10.1200\/JCO.2008.20.1764","article-title":"Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology","volume":"27","author":"Brugieres","year":"2009","journal-title":"J Clin Oncol"},{"key":"R54-20250804","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1200\/JCO.2005.11.075","article-title":"Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen\u2014a Pediatric Oncology Group phase III trial","volume":"23","author":"Laver","year":"2005","journal-title":"J Clin Oncol"},{"key":"R55-20250804","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1365-2141.2005.05910.x","article-title":"Recurrent childhood anaplastic large cell lymphoma: a retrospective analysis of registered cases in Japan","volume":"132","author":"Mori","year":"2006","journal-title":"Br J Haematol"},{"key":"R56-20250804","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/bjh.13167","article-title":"Haematopoietic stem cell transplantation for relapsed or refractory anaplastic large cell lymphoma: a study of children and adolescents in Japan","volume":"168","author":"Fukano","year":"2014","journal-title":"Br J Haematol"},{"key":"R57-20250804","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.2010.28.5999","article-title":"Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-Vinblastine Trial","volume":"28","author":"Le Deley","year":"2010","journal-title":"J Clin Oncol"},{"key":"R58-20250804","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1023\/A:1008352726155","article-title":"Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children\u2014a report from the French Society of Pediatric Oncology","volume":"11","author":"Brugieres","year":"2000","journal-title":"Ann Oncol"},{"key":"R59-20250804","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1002\/pbc.25187","article-title":"Advanced stage anaplastic large cell lymphoma in children and adolescents: results of ANHL0131, a randomized phase III trial of APO versus a modified regimen with vinblastine: a report from the Children\u2019s Oncology Group","volume":"61","author":"Alexander","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"R60-20250804","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/pbc.21817","article-title":"Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: final results of Children\u2019s Cancer Group Study 5941","volume":"52","author":"Lowe","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"R61-20250804","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1200\/JCO.2008.18.1487","article-title":"Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large cell lymphoma: results of a randomized trial of the EICNHL Group","volume":"27","author":"Brugi\u00e8res","year":"2009","journal-title":"J Clin Oncol"},{"key":"R62-20250804","first-page":"384","article-title":"Secondary acute promyelocytic leukemia in a child treated with epipodophyllotoxins","volume":"16","author":"Lopez-Andrew","year":"1994","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"R63-20250804","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J Clin Oncol"},{"key":"R64-20250804","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/bmt.2015.57","article-title":"Hematopoietic stem cell transplantation in relapsed ALK+ anaplastic large cell lymphoma in children and adolescents: a study on behalf of the SFCE and SFGM-TC","volume":"50","author":"Strullu","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"R65-20250804","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1002\/pbc.24722","article-title":"Ten-year follow-up of pediatric patients with non-Hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation","volume":"60","author":"Giulino-Roth","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"R66-20250804","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.bbmt.2009.09.021","article-title":"Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents","volume":"16","author":"Gross","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"R67-20250804","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/blood-2013-02-453175","article-title":"Umbilical cord blood transplantation: the first 25 years and beyond","volume":"122","author":"Ballen","year":"2013","journal-title":"Blood"},{"key":"R68-20250804","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1002\/pbc.24559","article-title":"Transplant-related mortality following allogeneic hematopoeitic stem cell transplantation for pediatric acute lymphoblastic leukemia: 25-year retrospective review","volume":"60","author":"Mateos","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"R69-20250804","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1200\/JCO.2013.54.2456","article-title":"Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T- cell lymphomas: results of a phase I study","volume":"32","author":"Fanale","journal-title":"J Clin Oncol"},{"key":"R70-20250804","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/bjh.13958","article-title":"Anaplastic large cell lymphoma in paediatric and young adult patients: a 2016 John Wiley & Sons Ltd","volume":"173","author":"Turner","year":"2016","journal-title":"Br J Haematol"},{"key":"R71-20250804","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(12)70344-3","article-title":"Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study","volume":"13","author":"Camidge","year":"2012","journal-title":"Lancet Oncol"},{"key":"R75-20250804","doi-asserted-by":"crossref","first-page":"djt378","DOI":"10.1093\/jnci\/djt378","article-title":"Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients","volume":"106","author":"Gambacorti Passerini","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"R76-20250804","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40425-016-0153-x","article-title":"PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?","volume":"4","author":"Grigg","year":"2016","journal-title":"J Immunother Cancer"},{"key":"R77-20250804","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","article-title":"CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms","volume":"25","author":"Parry","year":"2005","journal-title":"Mol Cell Biol"},{"key":"R78-20250804","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/nm863","article-title":"Blockade of B7-H1 improves myeloid dendritic cell\u2013mediated antitumor immunity","volume":"9","author":"Curiel","year":"2003","journal-title":"Nat Med"},{"key":"R79-20250804","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1007\/s00277-016-2764-1","article-title":"Pembrolizumab for relapsed anaplastic large cell lymphoma after allogeneic haematopoietic stem cell transplantation: Efficacy and safety","volume":"95","author":"Chan","year":"2016","journal-title":"Ann Hematol"},{"key":"R80-20250804","doi-asserted-by":"crossref","first-page":"e26902","DOI":"10.1002\/pbc.26902","article-title":"Efficacy of nivolumab in a patient with systemic refractory ALK+ anaplastic large cell lymphoma","volume":"65","author":"Rigaud","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"R81-20250804","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/mt.2016.82","article-title":"Superior therapeutic index in lymphoma therapy: CD30(+) CD34(+) hematopoietic stem cells resist a chimeric antigen receptor T-cell attack","volume":"24","author":"Hombach","year":"2016","journal-title":"Mol Ther"},{"key":"R82-20250804","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1172\/JCI94306","article-title":"Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes","volume":"127","author":"Ramos","year":"2017","journal-title":"J Clin Investig"},{"key":"R83-20250804","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1016\/j.ymthe.2017.06.008","article-title":"Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase","volume":"25","author":"Walker","year":"2017","journal-title":"Mol Ther"},{"key":"R84-20250804","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nm1769","article-title":"The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination","volume":"14","author":"Chiarle","year":"2008","journal-title":"Nat Med"},{"key":"R85-20250804","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1146\/annurev-immunol-032713-120136","article-title":"Adoptive immunotherapy for cancer or viruses","volume":"32","author":"Maus","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"R86-20250804","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1126\/science.8122112","article-title":"Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in nonHodgkin\u2019s lymphoma","volume":"263","author":"Morris","year":"1994","journal-title":"Science"},{"key":"R87-20250804","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1182\/blood.V93.9.3088.409k30_3088_3095","article-title":"A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation","volume":"93","author":"Lamant","year":"1999","journal-title":"Blood"},{"key":"R88-20250804","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0002-9440(10)64945-0","article-title":"ATIC-ALK: a novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35)","volume":"156","author":"Colleoni","year":"2000","journal-title":"Am J Pathol"},{"key":"R89-20250804","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1182\/blood.V94.9.3265","article-title":"TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations","volume":"94","author":"Hern\u00e1ndez","year":"1999","journal-title":"Blood"},{"key":"R90-20250804","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/gcc.10033","article-title":"Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor","volume":"34","author":"Cools","year":"2002","journal-title":"Genes Chromosomes Cancer"},{"key":"R91-20250804","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s12105-014-0530-z","article-title":"Current views and perspectives on classification of squamous intraepithelial lesions of the head and neck","volume":"8","author":"Gale","year":"2014","journal-title":"Head Neck Pathol"},{"key":"R92-20250804","doi-asserted-by":"crossref","first-page":"321","DOI":"10.4103\/0973-1482.73341","article-title":"Unresectable basaloid squamous cell carcinoma of the trachea treated with concurrent chemoradiotherapy: a case report with review of literature","volume":"6","author":"Joshi","year":"2010","journal-title":"J Cancer Res Ther"},{"key":"R93-20250804","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1007\/s00018-004-4275-9","article-title":"The emerging normal and dis-ease-related roles of anaplastic lymphoma kinase","volume":"61","author":"Pulford","year":"2004","journal-title":"Cell Mol Life Sci"},{"key":"R94-20250804","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/jcp.10472","article-title":"Anaplastic lymphoma kinase proteins in growth control and cancer","volume":"199","author":"Pulford","year":"2004","journal-title":"J Cell Physiol"},{"key":"R95-20250804","doi-asserted-by":"crossref","first-page":"5623","DOI":"10.1038\/sj.onc.1204594","article-title":"Translocations involving anaplastic lymphoma kinase (ALK)","volume":"20","author":"Duyster","year":"2001","journal-title":"Oncogene"},{"key":"R96-20250804","first-page":"2194","article-title":"Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin\/anaplastic lymphoma kinase-mediated lymphomagen-esis","volume":"61","author":"Slupianek","year":"2001","journal-title":"Cancer Res"},{"key":"R97-20250804","doi-asserted-by":"crossref","first-page":"6951","DOI":"10.1128\/MCB.18.12.6951","article-title":"Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-\u03b3 to mediate its mitogenicity","volume":"18","author":"Bai","year":"1998","journal-title":"Mol Cell Biol"},{"key":"R98-20250804","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1182\/blood-2016-05-717793","article-title":"Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target","volume":"129","author":"Werner","year":"2017","journal-title":"Blood"},{"key":"R99-20250804","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.4161\/cc.4.9.1985","article-title":"New and old functions of STAT3: a pivotal target for individualized treatment of cancer","volume":"4","author":"Inghirami","year":"2005","journal-title":"Cell Cycle"},{"key":"R100-20250804","doi-asserted-by":"crossref","first-page":"6200","DOI":"10.4049\/jimmunol.1300744","article-title":"Malignant transformation of CD4+T lymphocytes mediated by oncogenic kinase NPM\/ALK recapitulates IL-2\u2013induced cell signaling and gene expression reprogramming","volume":"191","author":"Marzec","year":"2013","journal-title":"J Immunol"},{"key":"R101-20250804","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nm1249","article-title":"Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target","volume":"11","author":"Chiarle","year":"2005","journal-title":"Nat Med"},{"key":"R102-20250804","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1182\/blood-2014-08-594507","article-title":"Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma","volume":"125","author":"Weilemann","year":"2015","journal-title":"Blood"},{"key":"R103-20250804","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/cancers10010021","article-title":"IRF4 mediates the oncogenic effects of STAT3 in anaplastic large cell lymphomas","volume":"10","author":"Bandini","year":"2018","journal-title":"Cancers"},{"key":"R104-20250804","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature07064","article-title":"IRF4 addiction in multiple myeloma","volume":"454","author":"Shaffer","year":"2008","journal-title":"Nature"},{"key":"R105-20250804","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2353\/ajpath.2009.080521","article-title":"Proteome-wide identification of novel binding partners to the oncogenic fusion gene protein, NPM-ALK, using tandem affinity purification and mass spectrometry","volume":"174","author":"Wu","year":"2009","journal-title":"Am J Pathol"},{"key":"R106-20250804","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1038\/onc.2010.505","article-title":"Oncogenic kinase NPM\/ALK induces expression of HIF1\u03b1 mRNA","volume":"30","author":"Marzec","year":"2011","journal-title":"Oncogene"},{"key":"R107-20250804","doi-asserted-by":"crossref","first-page":"6094","DOI":"10.1158\/0008-5472.CAN-14-0268","article-title":"ALK-dependent control of hypoxia-inducible factors mediates tumor growth and metastasis","volume":"74","author":"Martinengo","year":"2014","journal-title":"Cancer Res"},{"key":"R108-20250804","doi-asserted-by":"crossref","first-page":"20852","DOI":"10.1073\/pnas.0810958105","article-title":"Oncogenic kinase NPM\/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)","volume":"105","author":"Marzec","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"R109-20250804","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.4049\/jimmunol.181.4.2506","article-title":"\u03b3c-Signaling cytokines induce a regulatory T cell phenotype in malignant CD4+ T lymphocytes","volume":"181","author":"Kasprzycka","year":"2008","journal-title":"J Immunol"},{"key":"R110-20250804","doi-asserted-by":"crossref","first-page":"6627","DOI":"10.1182\/blood-2010-09-301994","article-title":"MiR-29a down-regulation in ALK-positive anaplastic large cell lymphomas contributes to apoptosis blockade through MCL-1 overexpression","volume":"117","author":"Desjobert","year":"2011","journal-title":"Blood"},{"key":"R111-20250804","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1172\/JCI29401","article-title":"Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and Bcl2A1 as critical target genes","volume":"116","author":"Piva","year":"2006","journal-title":"J Clin Investig"},{"key":"R112-20250804","doi-asserted-by":"crossref","first-page":"e64544","DOI":"10.1371\/journal.pone.0064544","article-title":"Identification of C\/EBP\u03b2 target genes in ALK+ anaplastic large cell lymphoma (ALCL) by gene expression profiling and chromatin immunoprecipitation","volume":"8","author":"Bonzheim","year":"2013","journal-title":"PLoS ONE"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002875","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T20:06:50Z","timestamp":1754338010000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,24]]},"references-count":107,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000002875","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,24]]},"assertion":[{"value":"2023-07-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}